BMY-BioNTech Partnership: A Potential Catalyst for Long-Term Gains?

Key Takeaways Bristol Myers and BioNTech's pumitamig plus chemo showed a 76.3% response rate in ES-SCLC.The phase II trial data supported dose selection for the pivotal ROSETTA LUNG-01 study.Pumitamig received FDA Orphan Drug status for small cell lung cancer treatment in 2025.Bristol Myers ((BMY) and partner BioNTech ((BNTX) recently presented interim data from a global randomized mid-stage study evaluating pumitamig plus chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC). Pumit ...